durvalumab
Overview
Durvalumab is an anti-PD-L1 monoclonal antibody immune checkpoint inhibitor with FDA approvals in non-small cell lung cancer, biliary tract cancer, and hepatocellular carcinoma.
Evidence in the corpus
- In genomic near-haploidization (GNH) diffuse pleural mesothelioma (DPM), a clinical trial of durvalumab plus platinum-pemetrexed in 3 GNH patients showed tumor shrinkage in all 3 and OS >=12 months; in contrast, only 1/44 (2%) non-GNH patients achieved partial response to ipilimumab/nivolumab or pembrolizumab PMID:38630790.
- Reviewed in HCC: durvalumab monotherapy ORR 10%; durvalumab + tremelimumab combination ORR 15% in phase I/II; combination NCT03298451 cited as active development strategy PMID:24798001
- Added to gemcitabine + cisplatin as standard first-line for advanced CCA (IHCH/EHCH/CHOL) showing incremental benefit; ARID1A-mutant tumors (18–23% iCCA) trend toward high MSI/TMB and ICI sensitivity PMID:25526346
- Authors advocate considering anti-PD-1/PD-L1 agents including durvalumab early in MSI-H metastatic EGC given the rapid failure on first-line cytotoxic therapy (median PFS 4.8 months) and durable immunotherapy responses observed in the MSK-IMPACT cohort PMID:29122777
- One of the anti-PD-L1 agents evaluated in the 240-patient MSK NSCLC cohort; TMB measured by MSK-IMPACT predicted durable clinical benefit independent of PD-L1 IHC (AUC 0.601 for TMB, 0.646 for PD-L1) across the full cohort including durvalumab-treated patients PMID:29337640
Resistance mechanisms
- Not directly characterized in the corpus.
Cancer types (linked)
Sources
This page was processed by crosslinker on 2026-05-14. - PMID:24798001
This page was processed by crosslinker on 2026-05-14. - PMID:25526346
This page was processed by crosslinker on 2026-05-14. - PMID:29122777
This page was processed by wiki-cli on 2026-05-15. - PMID:29337640
This page was processed by entity-page-writer on 2026-05-15.